MYCN and neuroblastoma: Furthermore, we found that SLC19A1 expression is upregulated by N-Myc, and that high SLC19A1 expression is correlated with neuroblastoma outcome, raising the possibility that a subset of high-risk patients with MYCN amplification and high SLC19A1 expression might be appropriate candidates for methotrexate therapy.